2024年高分文献精选：佰乐博生物引用产品前沿研究成果汇总

佰乐博生物作为全球领先的科研试剂服务商，致力于为生命科学领域的科研人员提供高质量的科研试剂与技术支持。佰乐博生物不仅在国内拥有广泛的科研合作网络，还与国际知名的品牌建立了紧密的合作关系，成为如AntibodySystem、ProteoGenix等多个国际顶尖品牌在亚洲区的独家代理商。通过为研究人员提供高质量的抗体、试剂、工具和技术，佰乐博生物助力科研进步，支持生命科学领域的前沿探索。

截至目前，引用佰乐博生物代理AntibodySystem产品的文献已累计达到214篇，总影响因子高达1303.9分。其中，发表在Nature、Cell、Immunity、Molecular Cancer 等顶级期刊的文献共有43篇。

佰乐博生物代理AntibodySystem等品牌与全球多所知名高校和科研机构合作，合作单位包括清华大学、北京大学、复旦大学、悉尼大学、麻省理工学院、东京大学和纽约大学等世界顶尖学术机构。研究领域涵盖广泛，涉及病毒学与疫苗研究、肿瘤研究、自身免疫疾病、神经科学与退行性疾病、抗体药物与细胞治疗、细菌寄生虫研究以及过敏反应等多个生命科学领域。

为了感谢广大科研工作者对AntibodySystem SAS的支持与信任，佰乐博和AntibodySystem SAS联合推出2024年度文献引用奖励活动。凡在SCI期刊上发表文章并使用AntibodySystem SAS全线产品的科研工作者，均可申请奖励，活动详情见《文献奖励》

小编精选了截至2024年引用产品发表的高分文献摘要，邀您一同鉴赏。

摘要：The Orthopoxvirus genus, especially variola virus (VARV), monkeypox virus (MPXV), remains a significant public health threat worldwide. The development of therapeutic antibodies against orthopoxviruses is largely hampered by the high cost of antibody engineering and manufacturing processes. mRNA-encoded antibodies have emerged as a powerful and universal platform for rapid antibody production. Herein, by using the established lipid nanoparticle (LNP)-encapsulated mRNA platform, we constructed four mRNA combinations that encode monoclonal antibodies with broad neutralization activities against orthopoxviruses. In vivo characterization demonstrated that a single intravenous injection of each LNP-encapsulated mRNA antibody in mice resulted in the rapid production of neutralizing antibodies. More importantly, mRNA antibody treatments showed significant protection from weight loss and mortality in the vaccinia virus (VACV) lethal challenge mouse model, and a unique mRNA antibody cocktail, Mix2a, exhibited superior in vivo protection by targeting both intracellular mature virus (IMV)-form and extracellular enveloped virus (EEV)-form viruses. In summary, our results demonstrate the proof-of-concept production of orthopoxvirus antibodies via the LNP-mRNA platform, highlighting the great potential of tailored mRNA antibody combinations as a universal strategy to combat orthopoxvirus as well as other emerging viruses.

摘要：

Persistent asymptomatic (PA) SARS-CoV-2 infections have been identified. The immune responses in these patients are unclear, and the development of effective treatments for these patients is needed. Here, we report a cohort of 23 PA cases carrying viral RNA for up to 191 days. PA cases displayed low levels of inflammatory and interferon response, weak antibody response, Persistent asymptomatic (PA) SARS-CoV-2 infections have been identified. The immune responses in these patients are unclear, and the development of effective treatments for these patients is needed. Here, we report a cohort of 23 PA cases carrying viral RNA for up to 191 days. PA cases displayed low levels of inflammatory and interferon response, weak antibody response, diminished circulating follicular helper T cells (cTfh), and inadequate specific CD4+and CD8+T-cell responses during infection, which is distinct from symptomatic infections and resembling impaired immune activation. Administration of a single dose of Ad5-nCoV vaccine to 10 of these PA cases elicited rapid and robust antibody responses as well as coordinated B-cell and cTfh responses, resulting in successful viral clearance. Vaccine-induced antibodies were able to neutralize various variants of concern and persisted for over 6 months, indicating long-term protection. Therefore, our study provides an insight into the immune status of PA infections and highlights vaccination as a potential treatment for prolonged SARS-CoV-2 infections.

摘要：Langya Henipavirus (LayV) infection is an emerging zoonotic disease that has been causing respiratory symptoms in China since 2019. For virus entry, LayV's genome encodes the fusion protein F and the attachment glycoprotein G. However, the structural and functional information regarding LayV-G remains unclear. In this study, we revealed that LayV-G cannot bind to the receptors found in other HNVs, such as ephrin B2/B3, and it shows different antigenicity from HeV-G and NiV-G. Furthermore, we determined the near full-length structure of LayV-G, which displays a distinct mushroom-shaped configuration, distinguishing it from other attachment glycoproteins of HNV. The stalk and transmembrane regions resemble the stem and root of mushroom and four downward-tilted head domains as mushroom cap potentially interact with the F protein and influence membrane fusion process. Our findings enhance the understanding of emerging HNVs that cause human diseases through zoonotic transmission and provide implication for LayV related vaccine development.

摘要：The fat mass and obesity-associated protein (FTO) is an RNA demethylase required for catalytic demethylation of N6-methyladenosine (m6A); it is highly expressed and functions as an oncogene in acute myeloid leukemia (AML). Currently, the overarching objective of targeting FTO is to precisely inhibit the catalytic activity. Meanwhile, whether FTO degradation also exerts antileukemic effects remains unknown. Herein, we designed the first FTO-targeting proteolysis targeting chimera (PROTAC) degrader QP73 using our FTO inhibitor Dac85—which potently inhibits FTO demethylation in AML cell lines—as a warhead. Notably, QP73 significantly induced FTO degradation in a time-, dose-, and ubiquitin–proteasome system-dependent manner and had superior antiproliferative activities to the FTO inhibitor Dac85 in various AML cell lines. Moreover, QP73 treatment significantly increased m6A modification on mRNA, promoted myeloid differentiation, and induced apoptosis of AML cells. Quantitative proteomics analysis showed that QP73 induced complete FTO degradation, upregulating RARA and ASB2 abundance and downregulating CEBPA, MYC, PFKP, and LDHB levels in AML cells. Lastly, QP73 exhibited antileukemic activity by increasing m6A modification and decreasing FTO levels in xenograft AML tumors. This proof-of-concept study shows that FTO-targeting PROTAC degraders can regulate the FTO signaling pathway and have potential antileukemia applications

摘要：Gold nanoparticle–based lateral flow immunoassays (AuNP LFIAs) are widely used point-of-care (POC) sensors for in vitro diagnostics. However, the sensitivity limitation of conventional AuNP LFIAs impedes the detection of trace biomarkers. Several studies have explored the size and shape factors of AuNPs and derivative nanohybrids, showing limited improvements or enhanced sensitivity at the cost of convenience and affordability. Here, we investigated surface chemistry on the sensitivity of AuNP LFIAs. By modifying surface ligands, a surface chemistry strategy involving weakly ionized AuNPs enables ultrasensitive naked-eye LFIAs (~100-fold enhanced sensitivity). We demonstrated how this surface chemistry–amplified immunoassay approach modulates nanointerfacial bindings to promote antibody adsorption and higher activity of adsorbed antibodies. This surface chemistry design eliminates complex nanosynthesis, auxiliary devices, or additional reagents while efficiently improving sensitivity with advantages: simplified fabrication process, excellent reproducibility and reliability, and ultrasensitivity toward various biomarkers. The surface chemistry using weakly ionized AuNPs represents a versatile approach for sensitizing POC sensors.

关于AntibodySystem

AntibodySystem SAS由具有30多年蛋白抗体开发经验的专家创立于法国，专注于生命科学和生物制药领域研究，总部位于法国斯特拉斯堡市。AntibodySystem自主开发高效、高产的真核重组表达系统，利用该系统生产高质量的重组蛋白、抗体产品。目前产品管线覆盖各种病毒研究蛋白/抗体质控品、in vivo功能性抗体、流式抗体、抗药药物靶点蛋白以及其他活性蛋白、PEG抗体、磷酸化抗体、抗DNA抗体、小分子抗体、RUO ELISA试剂盒、生物类似物。

关于佰乐博
武汉佰乐博生物（Biolab Reagents）由一群具有二十年工作经验的生命科学领域顶级研究者创立于2021年，凭借丰富的产品开发经验，利用全球领先的技术平台，引进和整合全球高品质的蛋白、抗体和试剂盒产品。目前，佰乐博生物作为法国AntibodySystem和ProteoGenix在亚洲的独家总代理，提供近30,000种生命科学试剂，核心产品涵盖蛋白、抗体和试剂盒，旨在为科研工作者提供专业、全面、可靠的试剂支持，推动生命科学研究的深入发展。